We envision a world where we feel tomorrow is another day.
News
- Chordia Therapeutics Director and Statutory Auditor Appointments
- Chordia named “Ministry of Education, Culture, Sports, Science and Technology (MEXT) Award” at Academic Startups 2022
- Chordia’s licensee Ono Pharmaceutical Co., Ltd. initiated Phase 1 Study of ONO-7018 (CTX-177), a MALT1 Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia in the U.S.
Science
Company
- Corporate Name
- Chordia Therapeutics Inc.
- Foundation
- November 1, 2017
- Head Office
- 26-1, Muraoka-Higashi 2-chome,
Fujisawa, Kanagawa 251-0012 Japan
- Tokyo Office
- 3-11-5,Nihonbashi-honcho,
Chuo-ku,Tokyo 103-0023 Japan
- Representative
- Hiroshi Miyake, Ph.D. CEO
